Komori
Changes in Officers4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding Changes in Officers

Minori Rosales will be promoted to Executive Vice President, Head of Global R&D Division and CMO. Outside Director Nomura Hiroshi (野村 博) will also resign.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Incoming appointee

1 item
Scheduled Appointment DateEffective 1 August 2026 (promotion of Minori Rosales)
Minori Rosales
New positionExecutive Vice President, Head of Global R&D Division and CMO

Departing officer

1 item
Date of departureEffective 31 July 2026 (resignation of Nomura Hiroshi (野村 博))
Nomura Hiroshi (野村 博)Next role stated
Former PositionOutside directors
New positionResignation

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Will not remain on the Board of Directors

Who is moving to which position
ItemDetails
Scheduled Appointment DateEffective 1 August 2026 (promotion of Minori Rosales)
Date of departureEffective 31 July 2026 (resignation of Nomura Hiroshi (野村 博))
Name of appointeeMinori Rosales
Appointee's new positionExecutive Vice President, Head of Global R&D Division and CMO
Name of departing officerNomura Hiroshi (野村 博)
Former position of departing officerOutside directors
New position of departing officerResignation
Whether the incumbent will remain in officeWill not remain on the Board of Directors
Items this document does not state (13)
Resolution dateAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for the changes or Nomura Hiroshi’s (野村 博) resignation is provided. The company states that, following Nomura Hiroshi’s (野村 博) resignation, the number of directors required under applicable laws and the Articles of Incorporation will still be met.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Changes in Officers | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori